Pariet

PreclinicalSmall molecule

Eisai

Pariet is one of 32 small molecule programs targeting Duodenal Ulcer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Duodenal UlcerActive, not recruiting

Duodenal UlcerPreclinical

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Duodenal Ulcer

#DrugCompanyPhaseTrials

Aleve

Alnylam Pharmaceuticals

Approved

1 2

Cytotec

Pfizer

Approved

1 3

Biaxin

Voltaren

Bayer Aspirin

Prevacid

10 7

Celebrex

PPhiladelphia Eye Associates

Approved

1 8

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

1 9

Doryx

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Flagyl

DDePuy Orthopaedics

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Duodenal Ulcer1 trial

A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer

Completed· Eisai logo

Eisai··NCT05208268·676 enrolled

TED1 trial

Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets

Completed·NNeutec Ar-Ge San ve Tic A.Ş·Phase 4·NCT03037606·48 enrolled

First-line1 trial

Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment

Completed·—·N/A·NCT05152004·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pariet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pariet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pariet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Eisai

Pariet

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Duodenal Ulcer1 trial

TED1 trial

First-line1 trial

References

Drug Info

Quick Facts

Related News